L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.
Saved in:
| Title: | L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial. |
|---|---|
| Authors: | Giordano FA; Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. Frank.Giordano@umm.de.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany. Frank.Giordano@umm.de.; Mannheim Institute for Intelligent Systems in Medicine (MIISM), University of Heidelberg, Mannheim, Germany. Frank.Giordano@umm.de., Layer JP; Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.; Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Turiello R; Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Friker LL; Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.; Institute of Neuropathology, University Hospital Bonn, University of Bonn, Bonn, Germany., Mirallas O; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Pregler BEF; Department of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany., Potthoff AL; Department of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany., Zeyen T; Department of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Weller J; Department of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Sperk E; Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.; Mannheim Cancer Center, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany., Sahm K; Department of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany., Oster C; Department of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.; DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen, Essen, Germany., Kebir S; Department of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.; DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen, Essen, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hambsch P; Department of Radiation Oncology, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany., Schäfer N; Department of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Kadzik S; Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Renovanz M; Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany., Pietsch T; Institute of Neuropathology, University Hospital Bonn, University of Bonn, Bonn, Germany., Bisdas S; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, United Kingdom., Sepúlveda-Sánchez JM; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Gómez-Puerto D; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Vieito M; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Platten M; Department of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany., Gkika E; Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Grauer OM; Department of Neurology, University Hospital Münster, University of Münster, Münster, Germany., Tabatabai G; Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany., Schneider M; Department of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany., Glas M; Department of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.; DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen, Essen, Germany.; Department of Neurology and Neurooncology, St. Marien Hospital Lünen, Lünen, Germany., Seidel C; Department of Radiation Oncology, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany., Herrlinger U; Department of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Hölzel M; Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany. michael.hoelzel@ukbonn.de. |
| Source: | Nature communications [Nat Commun] 2026 Apr 08; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 08. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-71362-7 |
